Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.85
NAS:IRWD's Cash to Debt is ranked lower than
65% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. NAS:IRWD: 0.85 )
Ranked among companies with meaningful Cash to Debt only.
NAS:IRWD' s Cash to Debt Range Over the Past 10 Years
Min: 0.85  Med: 42.32 Max: N/A
Current: 0.85
Equity to Asset 0.08
NAS:IRWD's Equity to Asset is ranked lower than
96% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.65 vs. NAS:IRWD: 0.08 )
Ranked among companies with meaningful Equity to Asset only.
NAS:IRWD' s Equity to Asset Range Over the Past 10 Years
Min: -1.86  Med: 0.34 Max: 0.74
Current: 0.08
-1.86
0.74
F-Score: 5
Z-Score: 0.52
M-Score: -2.04
WACC vs ROIC
10.07%
-75.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -21.43
NAS:IRWD's Operating margin (%) is ranked lower than
82% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. NAS:IRWD: -21.43 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:IRWD' s Operating margin (%) Range Over the Past 10 Years
Min: -1101.36  Med: -177.2 Max: -21.43
Current: -21.43
-1101.36
-21.43
Net-margin (%) -34.29
NAS:IRWD's Net-margin (%) is ranked lower than
83% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.71 vs. NAS:IRWD: -34.29 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:IRWD' s Net-margin (%) Range Over the Past 10 Years
Min: -1192.31  Med: -207.41 Max: -34.29
Current: -34.29
-1192.31
-34.29
ROE (%) -96.22
NAS:IRWD's ROE (%) is ranked lower than
93% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.47 vs. NAS:IRWD: -96.22 )
Ranked among companies with meaningful ROE (%) only.
NAS:IRWD' s ROE (%) Range Over the Past 10 Years
Min: -299.34  Med: -155.35 Max: -48.14
Current: -96.22
-299.34
-48.14
ROA (%) -12.58
NAS:IRWD's ROA (%) is ranked lower than
78% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. NAS:IRWD: -12.58 )
Ranked among companies with meaningful ROA (%) only.
NAS:IRWD' s ROA (%) Range Over the Past 10 Years
Min: -107.22  Med: -38.81 Max: -12.58
Current: -12.58
-107.22
-12.58
ROC (Joel Greenblatt) (%) -159.87
NAS:IRWD's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. NAS:IRWD: -159.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:IRWD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1275.86  Med: -355.09 Max: -159.87
Current: -159.87
-1275.86
-159.87
Revenue Growth (3Y)(%) -9.30
NAS:IRWD's Revenue Growth (3Y)(%) is ranked lower than
81% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NAS:IRWD: -9.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:IRWD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -29.8 Max: -5.4
Current: -9.3
EBITDA Growth (3Y)(%) 6.90
NAS:IRWD's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.50 vs. NAS:IRWD: 6.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:IRWD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -25.55 Max: 51.9
Current: 6.9
0
51.9
EPS Growth (3Y)(%) 13.70
NAS:IRWD's EPS Growth (3Y)(%) is ranked higher than
62% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NAS:IRWD: 13.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:IRWD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -21.3 Max: 54.1
Current: 13.7
0
54.1
» NAS:IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

IRWD Guru Trades in Q4 2015

Jim Simons 242,553 sh (+676.10%)
Paul Tudor Jones 26,514 sh (+111.87%)
Vanguard Health Care Fund 4,367,387 sh (unchged)
Samuel Isaly 1,237,800 sh (unchged)
Steven Cohen 1,537,900 sh (-4.62%)
» More
Q1 2016

IRWD Guru Trades in Q1 2016

Ken Fisher 235,675 sh (New)
Vanguard Health Care Fund 4,522,387 sh (+3.55%)
Samuel Isaly 1,237,800 sh (unchged)
Jim Simons Sold Out
Steven Cohen 1,180,500 sh (-23.24%)
Paul Tudor Jones 14,044 sh (-47.03%)
» More
Q2 2016

IRWD Guru Trades in Q2 2016

Joel Greenblatt 133,821 sh (New)
Paul Tudor Jones 34,118 sh (+142.94%)
Ken Fisher 242,450 sh (+2.87%)
Vanguard Health Care Fund 4,522,387 sh (unchged)
Samuel Isaly Sold Out
Steven Cohen 1,167,183 sh (-1.13%)
» More
Q3 2016

IRWD Guru Trades in Q3 2016

Joel Greenblatt 147,976 sh (+10.58%)
Ken Fisher 242,450 sh (unchged)
Vanguard Health Care Fund 4,522,387 sh (unchged)
Paul Tudor Jones 30,489 sh (-10.64%)
Steven Cohen 953,927 sh (-18.27%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:RDUS, NAS:MDCO, OTCPK:TSMRF, NAS:AKRX, OTCPK:INVVY, NYSE:CTLT, NAS:HZNP, NAS:DEPO, NAS:EGRX, NAS:PCRX, NAS:ENDP, NAS:SUPN, NAS:IPXL, OTCPK:KHTRF, NYSE:PTHN, NAS:MNTA, NYSE:DPLO, NAS:SGYP, NAS:AMPH, NYSE:LCI » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc is an entrepreneurial pharmaceutical company. It discovers, develops and commercializes differentiated medicines that improve patient's lives.

Ironwood Pharmaceuticals Inc was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company operates in one reportable segment; human therapeutics Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. It is advancing two therapeutic platforms, which include product opportunities in the areas of large unmet need, including irritable bowel syndrome with constipation, or IBS-C, and chronic idiopathic constipation, or CIC, vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, or GERD. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.

Ratios

vs
industry
vs
history
P/B 38.05
IRWD's P/B is ranked lower than
98% of the 953 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. IRWD: 38.05 )
Ranked among companies with meaningful P/B only.
IRWD' s P/B Range Over the Past 10 Years
Min: 5.45  Med: 11.87 Max: 47.65
Current: 38.05
5.45
47.65
P/S 9.32
IRWD's P/S is ranked lower than
80% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.91 vs. IRWD: 9.32 )
Ranked among companies with meaningful P/S only.
IRWD' s P/S Range Over the Past 10 Years
Min: 2.63  Med: 17.68 Max: 75.43
Current: 9.32
2.63
75.43
EV-to-EBIT -54.47
IRWD's EV-to-EBIT is ranked lower than
99.99% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.57 vs. IRWD: -54.47 )
Ranked among companies with meaningful EV-to-EBIT only.
IRWD' s EV-to-EBIT Range Over the Past 10 Years
Min: -58.2  Med: -12.5 Max: -4.2
Current: -54.47
-58.2
-4.2
EV-to-EBITDA -82.68
IRWD's EV-to-EBITDA is ranked lower than
99.99% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. IRWD: -82.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
IRWD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -88.3  Med: -13.7 Max: -4.4
Current: -82.68
-88.3
-4.4
Current Ratio 4.02
IRWD's Current Ratio is ranked higher than
72% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. IRWD: 4.02 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s Current Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.56 Max: 9.64
Current: 4.02
2.33
9.64
Quick Ratio 4.02
IRWD's Quick Ratio is ranked higher than
77% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. IRWD: 4.02 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s Quick Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.51 Max: 9.04
Current: 4.02
2.33
9.04
Days Sales Outstanding 1.79
IRWD's Days Sales Outstanding is ranked higher than
98% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.59 vs. IRWD: 1.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.05  Med: 8.18 Max: 889.76
Current: 1.79
0.05
889.76
Days Payable 759.85
IRWD's Days Payable is ranked higher than
99% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.65 vs. IRWD: 759.85 )
Ranked among companies with meaningful Days Payable only.
IRWD' s Days Payable Range Over the Past 10 Years
Min: 139.16  Med: 345.7 Max: 8217.61
Current: 759.85
139.16
8217.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.90
IRWD's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 434 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.70 vs. IRWD: -9.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRWD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -147.4  Med: -10.85 Max: 0
Current: -9.9
-147.4
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.53
IRWD's Price/Median PS Value is ranked higher than
88% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. IRWD: 0.53 )
Ranked among companies with meaningful Price/Median PS Value only.
IRWD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.17  Med: 1.02 Max: 3.52
Current: 0.53
0.17
3.52
Earnings Yield (Greenblatt) (%) -1.83
IRWD's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 1015 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. IRWD: -1.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IRWD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.59  Med: 0 Max: 0
Current: -1.83
-13.59
0

More Statistics

Revenue (TTM) (Mil) $239.8
EPS (TTM) $ -0.56
Beta1.01
Short Percentage of Float18.17%
52-Week Range $7.35 - 16.89
Shares Outstanding (Mil)146.22

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 256 355 479 713
EPS ($) -0.76 -0.42 0.32 1.58
EPS w/o NRI ($) -0.76 -0.42 0.32 1.58
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:IRWD

Headlines

Articles On GuruFocus.com
Ken Fisher's Best Investments: Credicorp, Ambev, Tata Motors Jul 11 2016 
A Look at Steven Cohen's Investment in Ironwood Pharmaceuticals Aug 25 2015 
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
Hedge Funds Are Buying Ironwood Pharmaceuticals, Inc. (IRWD) Nov 29 2016
IRONWOOD PHARMACEUTICALS INC Financials Nov 17 2016
Ironwood (IRWD) Presents Positive Phase III Data on Zurampic Nov 15 2016
ETFs with exposure to Ironwood Pharmaceuticals, Inc. : November 14, 2016 Nov 14 2016
Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of... Nov 13 2016
Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference Nov 10 2016
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10,... Nov 10 2016
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US :... Nov 09 2016
IRONWOOD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 07 2016
Ironwood (IRWD) Posts Narrower-than-Expected Loss in Q3 Nov 04 2016
Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns Nov 04 2016
Edited Transcript of IRWD earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 03 2016
Ironwood Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today Nov 03 2016
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 03 2016
Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update Nov 03 2016
Ironwood reports 3Q loss Nov 03 2016
Ironwood reports 3Q loss Nov 03 2016
Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update Nov 03 2016
Q3 2016 Ironwood Pharmaceuticals Inc Earnings Release - After Market Close Nov 03 2016
Ironwood Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference Nov 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)